CELLECTIS - ADR (CLLS) Stock Price, Quote, News and Overview
NASDAQ:CLLS - Nasdaq - US15117K1034 - ADR - Currency: USD
CLLS Quote, Performance and Key Statistics
2.52
+0.52 (+26%)
The current stock price of CLLS is 2.52 USD. In the past month the price increased by 69.38%. In the past year, price increased by 9.57%.
CLLS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.53 | 336.11B | ||
| AMGN | AMGEN INC | 14.77 | 164.85B | ||
| GILD | GILEAD SCIENCES INC | 15.01 | 144.54B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 120.61B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.71 | 60.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.87B | ||
| ARGX | ARGENX SE - ADR | 102.95 | 36.15B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.43 | 31.54B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.72B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.29B | ||
| INSM | INSMED INC | N/A | 19.72B | ||
| BIIB | BIOGEN INC | 8.31 | 19.27B |
Related stock screener links
About CLLS
Company Profile
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 224 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
Company Info
CELLECTIS - ADR
8, rue de la Croix Jarry
Paris ILE-DE-FRANCE 75013 FR
CEO: Andre Choulika
Employees: 219
Phone: 33181691600
CELLECTIS - ADR / CLLS FAQ
What is the stock price of CELLECTIS - ADR today?
The current stock price of CLLS is 2.52 USD. The price increased by 26% in the last trading session.
What is the ticker symbol for CELLECTIS - ADR stock?
The exchange symbol of CELLECTIS - ADR is CLLS and it is listed on the Nasdaq exchange.
On which exchange is CLLS stock listed?
CLLS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CELLECTIS - ADR stock?
13 analysts have analysed CLLS and the average price target is 7.87 USD. This implies a price increase of 212.22% is expected in the next year compared to the current price of 2.52. Check the CELLECTIS - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CELLECTIS - ADR worth?
CELLECTIS - ADR (CLLS) has a market capitalization of 252.82M USD. This makes CLLS a Micro Cap stock.
How many employees does CELLECTIS - ADR have?
CELLECTIS - ADR (CLLS) currently has 219 employees.
What are the support and resistance levels for CELLECTIS - ADR (CLLS) stock?
CELLECTIS - ADR (CLLS) has a support level at 1.44. Check the full technical report for a detailed analysis of CLLS support and resistance levels.
Is CELLECTIS - ADR (CLLS) expected to grow?
The Revenue of CELLECTIS - ADR (CLLS) is expected to grow by 63.01% in the next year. Check the estimates tab for more information on the CLLS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CELLECTIS - ADR (CLLS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CLLS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CLLS, evaluating the profitability, health, valuation and growth aspects
- CELLECTIS - ADR (CLLS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CELLECTIS - ADR (CLLS) Sales and EPS estimates to see what analysts future expectations are.
- CELLECTIS - ADR (CLLS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CELLECTIS - ADR (CLLS) Insider and Institutional Ownership to learn about the owners and their transactions.
- CELLECTIS - ADR (CLLS) Stock Chart to make your own analysis
- CELLECTIS - ADR (CLLS) Latest news and press-releases to stay up to date.
Does CELLECTIS - ADR (CLLS) stock pay dividends?
CLLS does not pay a dividend.
When does CELLECTIS - ADR (CLLS) report earnings?
CELLECTIS - ADR (CLLS) will report earnings on 2025-07-31.
What is the Price/Earnings (PE) ratio of CELLECTIS - ADR (CLLS)?
CELLECTIS - ADR (CLLS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
What is the Short Interest ratio of CELLECTIS - ADR (CLLS) stock?
The outstanding short interest for CELLECTIS - ADR (CLLS) is 0.39% of its float. Check the ownership tab for more information on the CLLS short interest.
CLLS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CLLS. When comparing the yearly performance of all stocks, CLLS is one of the better performing stocks in the market, outperforming 88.73% of all stocks.
CLLS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CLLS. Both the profitability and financial health of CLLS have multiple concerns.
CLLS Financial Highlights
Over the last trailing twelve months CLLS reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 45.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.12% | ||
| ROE | -41.34% | ||
| Debt/Equity | 0.65 |
CLLS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to CLLS. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -235.09% and a revenue growth 63.01% for CLLS